Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


COVID-19: Daily Top 10 Papers


  Tuberculosis

  Free Subscription


Articles published in J Infect

Retrieve available abstracts of 38 articles:
HTML format



Single Articles


    August 2021
  1. DAI Y, Xie L, Wang X, Zhang H, et al
    Depression increases the risk of tuberculosis: preliminary observations.
    J Infect. 2021 Aug 6. pii: S0163-4453(21)00369.
    PubMed    


    July 2021
  2. CHENDI BH, Tveiten H, Snyders CI, Tonby K, et al
    CCL1 and IL-2Ra differentiate Tuberculosis disease from latent infection Irrespective of HIV infection in low TB burden countries.
    J Infect. 2021 Jul 29. pii: S0163-4453(21)00379.
    PubMed     Abstract available


  3. RAJAMANICKAM A, Kumar NP, Padmapriyadarsini C, Nancy A, et al
    Latent tuberculosis co-infection is associated with heightened levels of humoral, cytokine and acute phase responses in seropositive SARS-CoV-2 infection.
    J Infect. 2021 Jul 27. pii: S0163-4453(21)00372.
    PubMed     Abstract available


  4. TAN Y, Deng Y, Yan X, Liu F, et al
    Nontuberculous mycobacterial pulmonary disease and associated risk factors in China: A prospective surveillance study.
    J Infect. 2021;83:46-53.
    PubMed     Abstract available


  5. SONG Y, Dong Y, Liao Y, Liang Z, et al
    Apoptotic caspases suppress Mycobacterium bovis-induced IFN-beta production in murine macrophage.
    J Infect. 2021;83:61-68.
    PubMed     Abstract available


    May 2021
  6. DILLARD LK, Martinez RX, Perez LL, Fullerton AM, et al
    Prevalence of aminoglycoside-induced hearing loss in drug-resistant tuberculosis patients: A systematic review: Ototoxic hearing loss in drug-resistant tuberculosis.
    J Infect. 2021 May 17. pii: S0163-4453(21)00252.
    PubMed     Abstract available


  7. SAM IK, Chen YY, Ma J, Li SY, et al
    TB-QUICK: CRISPR-Cas12b-assisted rapid and sensitive detection of Mycobacterium tuberculosis.
    J Infect. 2021 May 2. pii: S0163-4453(21)00219.
    PubMed     Abstract available


    February 2021
  8. LIU Q, Fang X, Chen X, Dai X, et al
    Letter to the editor: Application of the Xpert MTB/RIF technology in the diagnosis and treatment of osteoarticular tuberculosis.
    J Infect. 2021 Feb 20. pii: S0163-4453(21)00092.
    PubMed    


  9. WANG G, Jiang G, Jing W, Zong Z, et al
    Prevalence and molecular characterizations of seven additional drug resistance among multidrug-resistant tuberculosis in China: a subsequent study of a national survey.
    J Infect. 2021 Feb 5. pii: S0163-4453(21)00055.
    PubMed     Abstract available


  10. PATTERSON B, Abbara A, Collin S, Henderson M, et al
    Predicting drug-induced liver injury from anti-tuberculous medications by early monitoring of liver tests.
    J Infect. 2021;82:240-244.
    PubMed     Abstract available


    January 2021
  11. LOGAN C, Mullender C, Mirfenderesky M, Feasey N, et al
    Presentations and outcomes of central nervous system TB in a UK cohort: The high burden of neurological morbidity.
    J Infect. 2021;82:90-97.
    PubMed     Abstract available


  12. AHN CS, Shin JW, Kim JG, Lee WY, et al
    Spectrum of pleuropulmonary paragonimiasis: An analysis of 685 cases diagnosed over 22 years.
    J Infect. 2021;82:150-158.
    PubMed     Abstract available


  13. HEAD IM, Lazarus R
    Use of Xpert MTB/RIF in a low prevalence setting in the Southwest of England.
    J Infect. 2021;82:159-198.
    PubMed    


    December 2020
  14. IZZARD A, Wilders S, Smith C, Wickers M, et al
    Improved treatment completion for Tuberculosis patients: the case for a dedicated social care team.
    J Infect. 2020 Dec 23. pii: S0163-4453(20)30780.
    PubMed     Abstract available


  15. MARINE E, Loic H, Christelle GC, Pierre-Louis N, et al
    Improving tuberculosis management in prisons: impact of a rapid molecular point-of-care test.
    J Infect. 2020 Dec 4. pii: S0163-4453(20)30764.
    PubMed     Abstract available


  16. ADANKWAH E, Nausch N, Minadzi D, Abass MK, et al
    Interleukin-6 and Mycobacterium tuberculosis dormancy antigens improve diagnosis of tuberculosis.
    J Infect. 2020 Dec 2. pii: S0163-4453(20)30729.
    PubMed     Abstract available


  17. LIU XH, Xia L, Song B, Wang H, et al
    Stool-based Xpert MTB/RIF Ultra Assay as a tool for detecting pulmonary tuberculosis in children with abnormal chest imaging: a prospective cohort study.
    J Infect. 2020 Dec 1. pii: S0163-4453(20)30727.
    PubMed     Abstract available


    November 2020
  18. VAN ZYL CW, Loots DT, Solomons R, van Reenen M, et al
    Metabolic characterization of tuberculous meningitis in a South African paediatric population using (1)H NMR metabolomics.
    J Infect. 2020;81:743-752.
    PubMed     Abstract available


    September 2020
  19. SUDBURY EL, Clifford V, Messina NL, Song R, et al
    Mycobacterium tuberculosis-specific cytokine biomarkers to differentiate active TB and LTBI: A systematic review.
    J Infect. 2020 Sep 29. pii: S0163-4453(20)30631.
    PubMed     Abstract available


    August 2020
  20. SHI CL, Han P, Tang PJ, Chen MM, et al
    Clinical Metagenomic Sequencing for etiological diagnosis in pulmonary tuberculosis suspects.
    J Infect. 2020 Aug 5. pii: S0163-4453(20)30537.
    PubMed     Abstract available


  21. CAPOCCI SJ, Sewell J, Smith C, Cropley I, et al
    Cost effectiveness of testing HIV infected individuals for TB in a low TB/HIV setting.
    J Infect. 2020;81:289-296.
    PubMed     Abstract available


    July 2020
  22. KOMIYA K, Yamasue M, Takahashi O, Hiramatsu K, et al
    The COVID-19 pandemic and the true incidence of tuberculosis in Japan.
    J Infect. 2020 Jul 7. pii: S0163-4453(20)30462.
    PubMed    


    June 2020
  23. KIM H, Kim SH, Jung JH, Kim MJ, et al
    The usefulness of quantitative interferon-gamma releasing assay response for predicting active tuberculosis in kidney transplant recipients: a quasi-experimental study.
    J Infect. 2020 Jun 28. pii: S0163-4453(20)30452.
    PubMed     Abstract available


  24. MCGUIRE E, Rajagopal S, Vaikanthanathan T, Krutikov M, et al
    Extraspinal Articular Tuberculosis: an 11-year Retrospective Study of Demographic Features and Clinical Outcomes in East London.
    J Infect. 2020 Jun 21. pii: S0163-4453(20)30422.
    PubMed     Abstract available


  25. LAI CC, Yu WL
    The COVID-19 Pandemic and Tuberculosis in Taiwan.
    J Infect. 2020 Jun 10. pii: S0163-4453(20)30397.
    PubMed    


    May 2020
  26. ZHOU X, Zhang L, Lie L, Zhang Z, et al
    MxA suppresses TAK1-IKKalpha/beta-NF-kappaB mediated inflammatory cytokine production to facilitate Mycobacterium tuberculosis infection.
    J Infect. 2020 May 20. pii: S0163-4453(20)30286.
    PubMed     Abstract available


    April 2020
  27. LUO Y, Tang G, Lin Q, Mao L, et al
    Combination of mean spot sizes of ESAT-6 spot-forming cells and modified tuberculosis-specific antigen/phytohemagglutinin ratio of T-SPOT.TB assay in distinguishing between active tuberculosis and latent tuberculosis infection.
    J Infect. 2020 Apr 30. pii: S0163-4453(20)30264.
    PubMed     Abstract available


  28. ESTEVEZ O, Anibarro L, Garet E, Martinez A, et al
    Multi-parameter flow cytometry immunophenotyping distinguishes different stages of tuberculosis infection.
    J Infect. 2020 Apr 21. pii: S0163-4453(20)30218.
    PubMed     Abstract available


  29. HO J, Bokil NJ, Nguyen PTB, Nguyen TA, et al
    A Transcriptional Blood Signature Distinguishes Early Tuberculosis Disease from Latent Tuberculosis Infection and Uninfected Individuals in a Vietnamese Cohort.
    J Infect. 2020 Apr 21. pii: S0163-4453(20)30221.
    PubMed     Abstract available


    March 2020
  30. HU Y, Wen Z, Liu S, Cai Y, et al
    Ibrutinib Suppresses Intracellular Mycobacterium Tuberculosis Growth by Inducing Macrophage Autophagy.
    J Infect. 2020 Mar 11. pii: S0163-4453(20)30115.
    PubMed     Abstract available


    February 2020
  31. PETRUCCIOLI E, Chiacchio T, Navarra A, Vanini V, et al
    Effect of HIV-infection on QuantiFERON-Plus accuracy in patients with active tuberculosis and latent infection: QFT-Plus in HIV infected individuals.
    J Infect. 2020 Feb 22. pii: S0163-4453(20)30093.
    PubMed     Abstract available


  32. SUZUKAWA M, Takeda K, Akashi S, Asari I, et al
    Evaluation of cytokine levels using QuantiFERON-TB Gold Plus in patients with active tuberculosis.
    J Infect. 2020 Feb 22. pii: S0163-4453(20)30092.
    PubMed     Abstract available


    January 2020
  33. PERETOKINA I, Krylova LY, Antonova OV, Kholina MS, et al
    Reduced susceptibility and resistance to bedaquiline in clinical M. tuberculosis isolates.
    J Infect. 2020 Jan 22. pii: S0163-4453(20)30031.
    PubMed     Abstract available


  34. ZHOU Y, Anthony R, Wang S, Ou X, et al
    The epidemic of multidrug resistant tuberculosis in China in historical and phylogenetic perspectives.
    J Infect. 2020 Jan 20. pii: S0163-4453(20)30022.
    PubMed     Abstract available


  35. CAMPRUBI D, Gomila A, Grijota-Camino MD, Soldevila L, et al
    Infectiousness of patients with smear-negative pulmonary tuberculosis, assessed by Real-time Polymerase Chain Reaction, Xpert(R)MTB/RIF.
    J Infect. 2020 Jan 16. pii: S0163-4453(20)30026.
    PubMed     Abstract available


    October 2019
  36. SEKYERE JO, Reta MA, Maningi NE, Fourie PB, et al
    Molecular Epidemiology, Diagnostics and Mechanisms of Antibiotic Resistance in Mycobacterium tuberculosis complex in Africa: A Systematic Review of Current Reports.
    J Infect. 2019 Oct 16. pii: S0163-4453(19)30316.
    PubMed     Abstract available


  37. KARMAKAR M, Trauer JM, Ascher DB, Denholm JT, et al
    Hyper transmission of Beijing lineage Mycobacterium tuberculosis: Systematic review and Meta-analysis.
    J Infect. 2019 Oct 1. pii: S0163-4453(19)30287.
    PubMed     Abstract available


    September 2019
  38. MANALAN K, Green N, Arnold A, Cooke GS, et al
    A cost comparison of amikacin therapy with bedaquiline, for drug-resistant tuberculosis in the UK.
    J Infect. 2019 Sep 21. pii: S0163-4453(19)30277.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Tuberculosis is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: